SoftOx Solutions AS (Oslo) is a biotechnology company. With its patented technology, SoftOx will develop a portfolio of antimicrobial products to aid the global health challenges of both AMR and chronic skin infections. The company develops its products in collaboration with leading research institutions in the Nordic region. The work is supported by the Research Council of Norway and the EU. The first product will be introduced to the European market in 2020.
SoftOx has raised a total of NOK 190 million, of which NOK 50 million was raised before the IPO (Initial Public Offering) at an average price of NOK 13 per share. After the IPO, SoftOx have had the following placements:
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.